Matthew J. Graneto

4.0k citations

16 papers · 1.8k indexed · 1 hit paper · h-index 15

Co-authors: John J. Talley Carol M. Koboldt Karen Seibert Jeffery S. Carter David Brown Jaime L. Masferrer Ben S. Zweifel Roland S. Rogers
Topics: Inflammatory mediators and NSAID effects (12 papers)Synthesis and biological activity (7 papers)Synthesis of β-Lactam Compounds (4 papers)
Cited by: Pharmacology Organic Chemistry Toxicology
Journals: Journal of Biological Chemistry Journal of Medicinal Chemistry Journal of Pharmacology and Experimental Therapeutics
Partner nations: United States

In The Last Decade

Matthew J. Graneto

16 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2

2000 569 citations John J. Talley, David Brown et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Matthew J. Graneto

Since Specialization

Citations

This map shows the geographic impact of Matthew J. Graneto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew J. Graneto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew J. Graneto more than expected).

Fields of papers citing papers by Matthew J. Graneto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew J. Graneto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew J. Graneto. The network helps show where Matthew J. Graneto may publish in the future.

Co-authorship network of co-authors of Matthew J. Graneto

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew J. Graneto. A scholar is included among the top collaborators of Matthew J. Graneto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew J. Graneto. Matthew J. Graneto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Pharmacology of PF-4191834, a Novel, Selective Non-Redox 5-Lipoxygenase Inhibitor Effective in Inflammation and Pain 2010 ·Journal of Pharmacology and Experimental Therapeutics ·Jaime L. Masferrer,Ben S. Zweifel,Medora M. Hardy,Gary D. Anderson,Dawn Dufield,Luz Cortes-Burgos,Robert A. Pufahl,Matthew J. Graneto	36
2	The novel benzopyran class of selective cyclooxygenase-2 inhibitors-part I: The first clinical candidate 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jane L. Wang,(unknown),James R. Kiefer,Ravi G. Kurumbail,Jennifer L. Pawlitz,David Brown,(unknown),Matthew J. Graneto,Karen Seibert,John J. Talley	43
3	The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jane L. Wang,Karl Aston,David C. Limburg,(unknown),(unknown),Francis J. Koszyk,Bruce C. Hamper,David Brown,Matthew J. Graneto,John J. Talley,Timothy J. Maziasz,Jaime L. Masferrer,(unknown)	33
4	The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jane L. Wang,David C. Limburg,Matthew J. Graneto,John R. Springer,(unknown),Subo Liao,Jennifer L. Pawlitz,Ravi G. Kurumbail,Timothy J. Maziasz,John J. Talley,James R. Kiefer,(unknown)	284
5	CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain 2009 ·European Journal of Pharmacology ·Luz Cortes-Burgos,Ben S. Zweifel,Steven L. Settle,Robert A. Pufahl,Gary D. Anderson,Medora M. Hardy,(unknown),(unknown),(unknown),Zachary S. Stewart,Shanmugam Muthian,Matthew J. Graneto,Jaime L. Masferrer	30
6	Synthesis, Crystal Structure, and Activity of Pyrazole-Based Inhibitors of p38 Kinase 2007 ·Journal of Medicinal Chemistry ·Matthew J. Graneto,Ravi G. Kurumbail,Michael L. Vazquez,Huey‐Sheng Shieh,Jennifer L. Pawlitz,Jennifer M. Williams,William C. Stallings,(unknown),(unknown),Francis J. Koszyk,(unknown),Xiangdong Xu,Richard M. Weier,Gunnar J. Hanson,Robert J. Mourey,Robert P. Compton,Stephen J. Mnich,Gary D. Anderson,Joseph B. Monahan,Rajesh Devraj	55
7	A Selective IKK-2 Inhibitor Blocks NF-κB-dependent Gene Expression in Interleukin-1β-stimulated Synovial Fibroblasts 2003 ·Journal of Biological Chemistry ·Nandini Kishore,(unknown),Sumathy Mathialagan,Julia A. Guzova,Min Yao,Scott D. Hauser,(unknown),Sheri L. Bonar,(unknown),Lee D. Albee,Richard M. Weier,Matthew J. Graneto,(unknown),Thao Perry,Catherine S. Tripp	247
8	Radiosynthesis, in vitro validation, and in vivo evaluation of 18F-labeled COX-1 and COX-2 inhibitors. 2002 ·PubMed ·Timothy J. McCarthy,(unknown),Matthew J. Graneto,John J. Talley,Michael J. Welch	65
9	4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2breakdown → 2000 ·Journal of Medicinal Chemistry ·John J. Talley,David Brown,Jeffery S. Carter,Matthew J. Graneto,Carol M. Koboldt,Jaime L. Masferrer,William E. Perkins,Roland S. Rogers,Alexander F. Shaffer,(unknown),Ben S. Zweifel,Karen Seibert	569
10	N-[[(5-Methyl-3-phenylisoxazol-4-yl)- phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration 2000 ·Journal of Medicinal Chemistry ·John J. Talley,Stephen R. Bertenshaw,David Brown,Jeffery S. Carter,Matthew J. Graneto,Michael S. Kellogg,Carol M. Koboldt,Jinhua Yuan,(unknown),Karen Seibert	172
11	Design and synthesis of sulfonyl-substituted 4,5-diarylthiazoles as selective cyclooxygenase-2 inhibitors 1999 ·Bioorganic & Medicinal Chemistry Letters ·Jeffery S. Carter,D. Joseph Rogier,Matthew J. Graneto,Karen Seibert,Carol M. Koboldt,Yan Zhang,John J. Talley	28
12	Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors 1999 ·Bioorganic & Medicinal Chemistry Letters ·Jeffery S. Carter,Steven W. Kramer,John J. Talley,Thomas D. Penning,Paul W. Collins,Matthew J. Graneto,Karen Seibert,Carol M. Koboldt,Jaime L. Masferrer,Ben S. Zweifel	145
13	ChemInform Abstract: Synthesis and Biological Evaluation of the 1,5‐Diarylpyrazole Class of Cyclooxygenase‐2 Inhibitors: Identification of 4‐(5‐(4‐Methylphenyl)‐3‐ (trifluoromethyl)‐1H‐pyrazol‐1‐yl)benzenesulfonamide (SC‐58635, Celecoxib). 1997 ·ChemInform ·Thomas D. Penning,(unknown),Stephen R. Bertenshaw,(unknown),Paul W. Collins,(unknown),Matthew J. Graneto,(unknown),James W. Malecha,Julie M. Miyashiro,(unknown)	17
14	Conformationally restricted 1,5-diarylpyrazoles are selective COX-2 inhibitors 1996 ·Bioorganic & Medicinal Chemistry Letters ·Stephen R. Bertenshaw,John J. Talley,D. Joseph Rogier,Matthew J. Graneto,Carol M. Koboldt,Yan Zhang	39
15	3,4-diarylthiophenes are selective COX-2 inhibitors 1995 ·Bioorganic & Medicinal Chemistry Letters ·Stephen R. Bertenshaw,(unknown),D. Joseph Rogier,Matthew J. Graneto,Roland S. Rogers,Søren Kramer,Thomas D. Penning,Carol M. Koboldt,Amy W. Veenhuizen,(unknown),William E. Perkins	1
16	Multivalent sialyl-LeX: potent inhibitors of E-selectin-mediated cell adhesion; reagent for staining activated endothelial cells 1994 ·Glycobiology ·Joseph K. Welply,(unknown),Peter Scudder,Jeffery L. Keene,Kay O. Broschat,(unknown),(unknown),(unknown),Susan C. Howard,Jon J. Schmuke,Matthew J. Graneto,(unknown),Ian D. Manger,Gary S. Jacob	69

About Matthew J. Graneto

Matthew J. Graneto is a scholar working on Pharmacology, Organic Chemistry and Toxicology, having authored 16 papers that have together received 1.8k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (12 papers), Synthesis and biological activity (7 papers) and Synthesis of β-Lactam Compounds (4 papers). The work is most often cited by research in Pharmacology (728 citations), Organic Chemistry (1.1k citations) and Toxicology (77 citations). Matthew J. Graneto has collaborated with scholars based in United States. Frequent co-authors include John J. Talley, Carol M. Koboldt, Karen Seibert, Jeffery S. Carter, David Brown, Jaime L. Masferrer, Ben S. Zweifel, Roland S. Rogers, William E. Perkins and Alexander F. Shaffer. Their work appears in journals such as Journal of Biological Chemistry, Journal of Medicinal Chemistry and Journal of Pharmacology and Experimental Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact